Grund Nicholas Insider Trades

Insider Trading History

Track insider trading activity for Grund Nicholas. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Akebia Therapeutics
Akebia Therapeutics AKBA
Chief Commercial Officer
Holding Value $575k 592,994 shares
Last Trade
Feb 02, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$118k 84,829 shares
$1.39
$0.97
Akebia Therapeutics
Akebia Therapeutics AKBA
Chief Commercial Officer
Holding Value $627k 646,579 shares
Last Trade
Jan 30, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$739k 524,000 shares
$1.41
$0.97
Akebia Therapeutics
Akebia Therapeutics AKBA
Chief Commercial Officer
Holding Value $429k 442,579 shares
Last Trade
Feb 03, 2025 Sale (Open Market)Shares sold on the open market or in a private sale.
$117k 55,621 shares
$2.10
$0.97
Akebia Therapeutics
Akebia Therapeutics AKBA
Chief Commercial Officer
Holding Value $483k 498,200 shares
Last Trade
Jan 31, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$655k 292,300 shares
$2.24
$0.97
Akebia Therapeutics
Akebia Therapeutics AKBA
Chief Commercial Officer
Holding Value $441k 454,950 shares
Last Trade
Jan 31, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$764k 454,950 shares
$1.68
$0.97
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 84,805 shares
Last Trade
Mar 02, 2019 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 85,787 shares
Last Trade
Feb 25, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 61,787 shares
Last Trade
Feb 23, 2019 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 62,769 shares
Last Trade
Jan 04, 2019 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 70,517 shares
Last Trade
Mar 02, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 66,324 shares
Last Trade
Mar 02, 2018 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 48,517 shares
Last Trade
May 08, 2017 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 52,000 shares
Last Trade
Feb 23, 2017 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.00
AMAG Pharmaceuticals
AMAG Pharmaceuticals AMAG
Chief Commercial Officer
Holding Value $0 45,000 shares
Last Trade
Jan 04, 2016 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.00

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up